Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

61. Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders (PubMed)

Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders The objective of this review is to identify the features and components of a comprehensive system of services for people living with schizophrenia. A comprehensive system was conceived as one that served the full range of people with schizophrenia and was designed with consideration of the incidence and prevalence of schizophrenia. The system should provide access (...) to the full range of evidence-based services, should be recovery oriented, and should provide patient-centred care.A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders. The guidelines were rated by at least 2 raters, and recommendations adopted were primarily drawn from the National Institute for Clinical Excellence (2014) Guideline on Psychosis and Schizophrenia in adults and the Scottish Intercollegiate Guidelines Network guidelines

Full Text available with Trip Pro

2017 CPG Infobase

62. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders (PubMed)

Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders The objective of this article is to identify best practices in the diagnosis and assessment of patients with schizophrenia spectrum and other psychotic disorders. The diagnosis and assessment may occur in a range of situations from the emergency room to the outpatient clinic and at different stages of the disorder. The focus may be on acute exacerbations of illness (...) , residual symptoms, levels of function, or changes in the response to treatment.A systematic search was conducted for guidelines published in the last 5 years for schizophrenia and schizophrenia spectrum disorders. The guidelines were rated by at least 2 raters, and recommendations adopted on the diagnosis and assessment were primarily drawn from the American Psychiatric Association practice guidelines for the psychiatric evaluation of adults and the National Institute for Health and Care Excellence

Full Text available with Trip Pro

2017 CPG Infobase

63. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders (PubMed)

Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders.We reviewed guidelines (...) that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context

Full Text available with Trip Pro

2017 CPG Infobase

64. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults (PubMed)

Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults It is generally recognised that psychosocial interventions are essential components of the effective treatment of schizophrenia in adults. A considerable body of research is being published regarding the effectiveness of such interventions. In the current article, we derive recommendations reflecting the current state of evidence for their effectiveness.Recommendations were formulated on the basis of a review (...) be provided with education about the nature of schizophrenia and its treatment. Several recent innovative psychosocial approaches to treatment are awaiting more thorough evaluation.There continues to be strong evidence for the effectiveness of several psychosocial interventions in improving outcomes for adults with schizophrenia. In the past decade, innovative interventions have been described, several of which are the subject of ongoing evaluative research.

Full Text available with Trip Pro

2017 CPG Infobase

65. Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth (PubMed)

Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth A panel of experts, including researchers, clinicians and people with lived experience, was brought together to develop the new Canadian schizophrenia guidelines for the psychosocial treatment of children and youth with schizophrenia or psychotic disorders.The ADAPTE process, which relies on adapting existing high-quality guidelines, was used. Existing guidelines for children and youth (mostly from (...) treatment of children and youth with schizophrenia or psychotic disorders report evidence-based treatments as well as important considerations for providers who work with this clientele. More studies with children and youth with schizophrenia and psychotic disorders are warranted. If followed, these guidelines should facilitate the recovery of children and youth with schizophrenia or psychotic disorders as well as the recovery of their families.

Full Text available with Trip Pro

2017 CPG Infobase

66. Physical health and drug safety in individuals with schizophrenia (PubMed)

Physical health and drug safety in individuals with schizophrenia While antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require the attention and care of prescribers.We used the ADAPTE process to adapt existing guideline recommendations from the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN

Full Text available with Trip Pro

2017 CPG Infobase

67. Guidelines for the pharmacotherapy of schizophrenia in adults (PubMed)

Guidelines for the pharmacotherapy of schizophrenia in adults The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines (...) and recommendations to create an adapted guideline.Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.In most cases, evidence-based recommendations are made

Full Text available with Trip Pro

2017 CPG Infobase

68. Yoga as part of a package of care versus standard care for schizophrenia. (PubMed)

Yoga as part of a package of care versus standard care for schizophrenia. Yoga is an ancient spiritual practice that originated in India and is currently accepted in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine the efficacy of yoga delivered as a package of care versus standard care.To examine the effects of yoga as a package of care versus standard care.We searched the Cochrane Schizophrenia Group Trials Register (...) (latest 30 March 2017) which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSS, AMED, PsychINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga as a package of care with standard-care control.The review authors independently selected

Full Text available with Trip Pro

2017 Cochrane

69. Yoga versus non-standard care for schizophrenia. (PubMed)

Yoga versus non-standard care for schizophrenia. Yoga is an ancient spiritual practice that originated in India and is currently accepted in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia as an alternative or adjunctive treatment.To systematically assess the effects of yoga versus non-standard care for people with schizophrenia.The Information Specialist of the Cochrane Schizophrenia Group searched their specialised Trials Register (...) (latest 30 March 2017), which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSIS, AMED, PsycINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia and comparing yoga with non-standard care. We included trials that met our selection criteria

Full Text available with Trip Pro

2017 Cochrane

70. Chlorpromazine versus penfluridol for schizophrenia. (PubMed)

Chlorpromazine versus penfluridol for schizophrenia. The efficacy of chlorpromazine, a benchmark antipsychotic, has not been fully assessed in direct comparison with different individual antipsychotics. Penfluridol is another old antipsychotic with a long half-life so one oral dose may last up to one week. This could confer advantage.To assess the clinical effects of chlorpromazine compared with penfluridol for adults with schizophrenia.On 31 March 2017, we searched the Cochrane Schizophrenia (...) Group's Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There are no language, date, document type, or publication status limitations for inclusion of records in the register.We included all randomised clinical trials focusing on chlorpromazine versus penfluridol for adults with schizophrenia or related disorders. Outcomes of interest were death, service utilisation, global state, mental

Full Text available with Trip Pro

2017 Cochrane

71. Art therapy for schizophrenia?

Art therapy for schizophrenia? Art therapy is used as a complementary treatment to antipsychotics in schizophrenia. However, its effectiveness is not clear. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple databases. We identified five systematic reviews including 20 studies overall, of which four were randomized trials. We extracted data and prepared summary of findings tables using the GRADE method. We concluded it is not clear whether (...) art therapy leads to clinical improvement in schizophrenia because the certainty of the evidence is very low.

Full Text available with Trip Pro

2017 Medwave

72. Is electroconvulsive therapy effective as augmentation in clozapine-resistant schizophrenia?

Is electroconvulsive therapy effective as augmentation in clozapine-resistant schizophrenia? Clozapine is considered to be the most effective antipsychotic drug for patients with treatment resistant schizophrenia, but up to a third of the patients do not respond to this treatment. Various strategies have been tried to augment the effect of clozapine in non-responders, one of these strategies being electroconvulsive therapy. However, its efficacy and safety are not yet clear. Searching (...) in Epistemonikos database, which is maintained by screening 30 databases, we identified six systematic reviews including 55 studies, among them six randomized controlled trials addressing clozapine-resistant schizophrenia. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded electroconvulsive therapy probably augments response to clozapine in patients with treatment resistant schizophrenia, but it is not possible to determine if it leads

Full Text available with Trip Pro

2017 Medwave

73. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia?

Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia? Clozapine constitutes the treatment of choice in patients with schizophrenia with persisting symptoms despite antipsychotics at adequate dose and treatment duration. However, an important proportion does not respond to optimal doses of clozapine, so the addition of a second antipsychotic might increase clinical response. Searching in Epistemonikos database, which is maintained by screening (...) multiple databases, we identified 17 systematic reviews comprising 62 studies addressing the question of this article, including 26 randomized trials. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded adding a second antipsychotic to clozapine in patients with refractory schizophrenia probably leads to little or no difference in clinical response, and increases adverse effects.

Full Text available with Trip Pro

2017 Medwave

74. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark

Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark Research on the association between schizophrenia and the quality of care and clinical outcomes of heart failure (HF) remains sparse. This nationwide study compared the quality of care and clinical outcomes of HF among Danish patients with and without schizophrenia. In a population-based cohort study, we identified 36,718 patients with incident HF with hospital contacts, including 108 with schizophrenia (...) , using Danish registries between 2004 and 2013. High quality of HF care was defined as receiving ≥ 80% guideline-recommended process-performance measures of care. Potential predictors of HF care among patients with schizophrenia included patient-specific factors (age, gender, Global Assessment of Functioning [GAF] score, alcohol or drug abuse, duration of schizophrenia); provider-specific factors (quality of schizophrenia care); and system-specific factors (patient-volume defined as hospital

2017 EvidenceUpdates

75. Latuda (lurasidone) - schizophrenia

Latuda (lurasidone) - schizophrenia Latuda (lurasidone) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Latuda (lurasidone) Conclusion Latuda contains lurasidone, which is a 2nd generation antipsychotic authorised for the treatment of schizophrenia in adults aged 18 years and over. Lurasidone efficacy in the PANSS total score is on a par with other 2nd generation antipsychotics, but has been demonstrated to be different from the other antipsychotics (...) , there are minimal effects on metabolic parameters as well as the QT interval. A line of antipsychotics with a similar efficacy profile are already sold on the market as generic products, which makes them significantly cheaper than Latuda. It is IRF's overall assessment that Latuda should not be a first-line treatment for schizophrenia in adults, but it could be relevant in cases where the minimisation of metabolic and cardiovascular effects is of utmost importance or in patients who are extremely concerned

2017 Danish Pharmacotherapy Reviews

76. Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines

Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines (...) Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines Published on: August 31, 2017 Project Number: RC0917-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of 3-month injectable paliperidone palmitate for the treatment of adults with schizophrenia? What are the evidence-based guidelines

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

77. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study (PubMed)

Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study Postinjection delirium/sedation syndrome (PDSS) has been reported uncommonly during treatment with olanzapine long-acting injection (LAI), a sustained-release formulation of olanzapine.The primary aim of the study was to estimate the incidence per injection and per patient of PDSS events in adult patients with schizophrenia who were (...) receiving olanzapine LAI in real-world clinical practice. Secondary aims were to further characterise the clinical presentation of PDSS events, to identify potential risk factors associated with PDSS events and to characterise hospitalisations at baseline and post-baseline.A prospective observational study of adult patients with schizophrenia receiving olanzapine LAI from 24 countries. Data were collected on patient characteristics, olanzapine LAI treatment and any adverse events (AEs). All AEs were

Full Text available with Trip Pro

2017 BJPsych open

78. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.To determine the effects (...) of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders.This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through

Full Text available with Trip Pro

2017 EvidenceUpdates

79. Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study (PubMed)

Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study Coronary heart disease (CHD) is a leading cause of premature death in patients with schizophrenia. CHD risk in Lebanese patients with schizophrenia remains unknown.To (i) evaluate CHD risk of patients with schizophrenia in Lebanon; and (ii) detect the modifiable and non-modifiable factors affecting this risk.Cross-sectional study of 329 patients with schizophrenia aged 20-75 years. Ten-year hard CHD (...) , confidence interval [CI] 1.54-4.64), a longer duration of schizophrenia (OR 1.03, CI 1.01-1.05), a history of other medical illnesses (OR 2.02, CI 1.18-3.47), and in those participating in art therapy (OR 2.13, CI 1.25-3.64) or therapeutic education (OR 1.93, CI 0.93-4.01). Ten-year hard CHD risk was lower in patients receiving risperidone (OR 0.23, CI 0.08-0.68), any anti-epileptic (OR 0.41, CI 0.24-0.73), or any benzodiazepine (OR 0.33, CI 0.17-0.66) medication.CHD is prevalent in patients

Full Text available with Trip Pro

2017 Journal of comorbidity

80. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence

Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing.To summarize and compare the meta-analytically determined efficacy (...) be recommended for patients with schizophrenia based on the current meta-analytic literature.

Full Text available with Trip Pro

2017 EvidenceUpdates